TIAM
RNAC icon

TT International Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

TT International Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,667
Closed -$585K – 79
2021
Q2 		$585K Hold
4,667
– – 0.03% 68
2021
Q1 		$634K Buy
4,667
+4,200
+899% +$521K 25.24% 1
2020
Q4 		$424K Buy
+467
New +$40.5K 0.02% 58

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TT International Asset Management's RNAC Position: Q3 2021 in Review

TT International Asset Management sold out of Cartesian Therapeutics (RNAC) in Q3 2021, closing a stake of 4,667 shares — an estimated $585K sold.

TT International Asset Management first reported a position in RNAC in Q4 2020 and held it in 3 quarters. The position peaked at $634K in Q1 2021. 103 funds tracked by Wall St. Rank hold RNAC as of Q3 2021.

  • TT International Asset Management reported no remaining Cartesian Therapeutics position as of Q3 2021 after selling out during the quarter.
  • TT International Asset Management sold 4,667 Cartesian Therapeutics shares in Q3 2021, an estimated $585K.
  • TT International Asset Management first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 3 quarters.
  • TT International Asset Management's Cartesian Therapeutics position peaked at $634K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2021.

Based on TT International Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.